EVAX Inc. is the manufacturing and commercialization subsidiary of Enepret Inc., which pioneered the reliable, renewable production of triterpene oils, including squalene, and formulation into oil-in-water adjuvants more than 5 years ago.  With a multi-million dollar contract from the National Institutes of Health and private investment, EVAX Inc. has now begun GMP manufacturing of triterpene oils and oil-in-water adjuvants. This scalable and sustainable solution promises to revolutionize and expedite vaccine development from pre-clinical to clinical trials, meeting all federal agency standards for existing and new vaccines.